"FDA commissioner Marty Makary stated that psychedelics 'have the potential to address the nation's mental health crisis, including conditions like treatment resistant depression, alcoholism and other serious mental health and substance abuse conditions.'"
"The Trump administration is making once-illicit substances its ally, as evidenced by the FDA's fast-tracked approval for new psychedelic research following an executive order from President Trump."
"On April 18, Trump ordered the FDA commissioner to grant priority vouchers to psychedelic drugs that have received Breakthrough Therapy designations, aiming to eliminate delays in the review process."
"The Justice Department announced a new hearing to reclassify marijuana from a Schedule I drug to a Schedule II drug, indicating a significant shift in drug policy."
The FDA has granted an expedited review process for three experimental psychedelic drugs, reducing the review time from 10-12 months to 1-2 months. This includes research on psilocybin for depression and methylone for PTSD. FDA commissioner Marty Makary stated that psychedelics could help with the mental health crisis. The Trump administration is also working to make marijuana safer and more accessible, with plans to reclassify it from Schedule I to Schedule II, indicating a shift in drug policy.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]